A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder
Time to relapse was similar between continued adjunctive brexpiprazole and brexpiprazole withdrawal; in both groups, ∼80% of stabilised patients remained relapse free at their last visit. Adjunctive brexpiprazole therapy was generally well tolerated over up to 46 weeks, with minimal adverse effects following brexpiprazole withdrawal.ClinicalTrials.gov identifier: NCT03538691. Funding: Otsuka, Lundbeck.
Authors
- Kripa Sundararajan
- Claudette Brewer
- Roger S. McIntyre (ORCID: https://orcid.org/0000-0003-4733-2523)
- Na Jin (ORCID: https://orcid.org/0000-0001-7611-8927)
- Nanco Hefting (ORCID: https://orcid.org/0000-0003-3310-3439)
- Michael E. Thase
- Mary Hobart
- Saloni Behl
Institutions
- Lundbeck (Denmark) (DK)
- University of Toronto (CA)
- Veterans Health Administration (US)
- Otsuka (United States) (US)
- Brain and Cognition Discovery Foundation (CA)
- University of Pennsylvania (US)
Publication Details
- Journal
- Acta Neuropsychiatrica
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1017/neu.2024.32
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00